Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

Abstract To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival and to characterize prognostic factors affecting survival in metastatic castration-resistant prostate cancer (mCRPC) patients. A total of 250 patients treated with E or AA in 5 centers were included. The...

Full description

Bibliographic Details
Main Authors: Ayşe Demirci, Cemil Bilir, Burcu Gülbağcı, İlhan Hacıbekiroğlu, İbrahim V. Bayoğlu, İrem Bilgetekin, Sinan Koca, Havva Y. Çınkır, Nadiye Akdeniz, Deniz Gül, Ceyhun Varım, Umut Demirci, Berna Öksüzoğlu
Format: Article
Language:English
Published: Nature Publishing Group 2021-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-93659-x

Internet

https://doi.org/10.1038/s41598-021-93659-x

Similar Items